The University of Southampton
University of Southampton Institutional Repository

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
Purpose: AURA was an international, retrospective, observational study that monitored the real-life use and effectiveness of ranibizumab injections in patients with neovascular age-related macular degeneration (nAMD). This paper reports the findings from the UK.

Methods: Patients who started treatment with ranibizumab between January 1, 2009, and August 31, 2009, and had documented follow-up to the end of their treatment and/or monitoring or until August 31, 2011, were retrospectively monitored; the diagnosis and subsequent decision to treat was made by the patient’s own physician. Assessments included the change in visual acuity (standardized letter count) during the first and second years after start of ranibizumab therapy and resource utilization.

Results: Four hundred and ten patients from 13 UK centers were analyzed. The mean (standard deviation [SD]) letter score at baseline was 55.0 (17.8). The mean (SD) change in visual acuity from baseline was +6.0 (15.4) letters at year 1 and +4.1 (16.9) at year 2. Most of the patients (86.6%) completed a 3-month loading phase; the visual improvements were numerically higher in these patients. Over 2 years, the mean (SD) number of clinic visits and injections was 18.4 (5.0) and 9.0 (4.7), respectively. Resource use and visual acuity gains were greater than those observed in the global population, which included other countries enrolled in AURA (Canada, France, Germany, Ireland, Italy, the Netherlands, and Venezuela). When patients were stratified according to severity of nAMD (based on letter count at baseline), the mean change in visual acuity score at years 1 and 2 was also higher for the UK than for the global population across all subgroups.

Conclusion: Monitoring and treatment rates were high in the UK, resulting in better visual acuity outcomes compared with other included countries. This suggests that translation of clinical study outcomes into real-life settings is achievable, but at the expense of higher resource utilization than is currently the norm in most developed countries.
1177-5467
87-96
Hykin, P.
50c663b1-b92b-48f2-bec6-f1da0729d9a7
Chakravarthy, U.
98345bdd-d823-4aad-b205-0045413574d7
Lotery, A.J.
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
McKibbin, M.
65e194c2-62e4-4a79-b442-ef92de81e625
Napier, J.
de27ed70-e9d9-4499-9e55-b08b9c966d3a
Sivaprasad, S.
451d388e-50f3-4cfb-b963-e73461eed920
Hykin, P.
50c663b1-b92b-48f2-bec6-f1da0729d9a7
Chakravarthy, U.
98345bdd-d823-4aad-b205-0045413574d7
Lotery, A.J.
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
McKibbin, M.
65e194c2-62e4-4a79-b442-ef92de81e625
Napier, J.
de27ed70-e9d9-4499-9e55-b08b9c966d3a
Sivaprasad, S.
451d388e-50f3-4cfb-b963-e73461eed920

Hykin, P., Chakravarthy, U., Lotery, A.J., McKibbin, M., Napier, J. and Sivaprasad, S. (2016) A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. Clinical Ophthalmology, 10, 87-96. (doi:10.2147/OPTH.S92627). (PMID:26834453)

Record type: Article

Abstract

Purpose: AURA was an international, retrospective, observational study that monitored the real-life use and effectiveness of ranibizumab injections in patients with neovascular age-related macular degeneration (nAMD). This paper reports the findings from the UK.

Methods: Patients who started treatment with ranibizumab between January 1, 2009, and August 31, 2009, and had documented follow-up to the end of their treatment and/or monitoring or until August 31, 2011, were retrospectively monitored; the diagnosis and subsequent decision to treat was made by the patient’s own physician. Assessments included the change in visual acuity (standardized letter count) during the first and second years after start of ranibizumab therapy and resource utilization.

Results: Four hundred and ten patients from 13 UK centers were analyzed. The mean (standard deviation [SD]) letter score at baseline was 55.0 (17.8). The mean (SD) change in visual acuity from baseline was +6.0 (15.4) letters at year 1 and +4.1 (16.9) at year 2. Most of the patients (86.6%) completed a 3-month loading phase; the visual improvements were numerically higher in these patients. Over 2 years, the mean (SD) number of clinic visits and injections was 18.4 (5.0) and 9.0 (4.7), respectively. Resource use and visual acuity gains were greater than those observed in the global population, which included other countries enrolled in AURA (Canada, France, Germany, Ireland, Italy, the Netherlands, and Venezuela). When patients were stratified according to severity of nAMD (based on letter count at baseline), the mean change in visual acuity score at years 1 and 2 was also higher for the UK than for the global population across all subgroups.

Conclusion: Monitoring and treatment rates were high in the UK, resulting in better visual acuity outcomes compared with other included countries. This suggests that translation of clinical study outcomes into real-life settings is achievable, but at the expense of higher resource utilization than is currently the norm in most developed countries.

Text
OPTH-92627-a-retrospective-study-of-the-real-life-utilization-and-effec_011316.pdf - Version of Record
Available under License Other.
Download (1MB)

More information

Accepted/In Press date: 11 November 2015
Published date: 13 January 2016
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 390359
URI: http://eprints.soton.ac.uk/id/eprint/390359
ISSN: 1177-5467
PURE UUID: f293a6c2-0f9e-4a72-a83a-a280b9915457
ORCID for A.J. Lotery: ORCID iD orcid.org/0000-0001-5541-4305

Catalogue record

Date deposited: 24 Mar 2016 14:06
Last modified: 17 Dec 2019 01:49

Export record

Altmetrics

Contributors

Author: P. Hykin
Author: U. Chakravarthy
Author: A.J. Lotery ORCID iD
Author: M. McKibbin
Author: J. Napier
Author: S. Sivaprasad

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×